GPC3 and hepatocellular carcinoma: More recently, different phase I clinical trial studies report encouraging initial safety data on the use of CAR-GPC3 T cell therapy for the treatment of advanced (NCT02395250, NCT05003895, [16]) and refractory GPC3-expressing HCC (NCT03146234).